UCLA

Summary

UCLA is a medical facility located in Santa Monica, California. This center is recognized for care of Lung Cancer, Pancreatic Cancer, Solid Tumors, Breast Cancer, Cancer and other specialties. UCLA is involved with conducting 83 clinical trials across 126 conditions. There are 23 research doctors associated with this hospital, such as Zev A. Wainberg, Lee Rosen, MD, J. Randolph Hecht, MD, and John Shen, M.D..

Top PIs

Clinical Trials running at UCLA

Colorectal Cancer

Lung Cancer

Pancreatic Cancer

Solid Tumors

Ovarian Cancer

Breast Cancer

Cancer

Gastrointestinal Stromal Tumor

Postoperative Pain

Kidney Cancer

Amivantamab + Chemotherapy vs Cetuximab + Chemotherapy

for Colorectal Cancer

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer.

Recruiting

2 awards

Phase 3

4 criteria

Amivantamab + FOLFIRI

for Colorectal Cancer

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.

Recruiting

2 awards

Phase 3

4 criteria

[225Ac]-FPI-2068

for Cancer

This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of \[225Ac\]-FPI-2068, \[111In\]-FPI-2107, and FPI-2053 in metastatic and/or recurrent solid tumors (HNSCC, NSCLC, mCRC, PDAC, GC, RCC).

Recruiting

1 award

Phase 1

6 criteria